Loading...
•
Dec 31, 2020
EyePoint Pharmaceuticals Q4 2020 Earnings Report
EyePoint Pharmaceuticals reported financial results for Q4 2020, marked by a decrease in total net revenue compared to the same period in 2019, alongside strategic corporate developments including advancements in EYP-1901 and balance sheet improvements.
Key Takeaways
EyePoint Pharmaceuticals reported a net revenue of $7.1 million for Q4 2020, a decrease from $8.6 million in Q4 2019. The company experienced a net loss of $15.5 million, or $1.07 per share, compared to a net loss of $10.4 million, or $0.98 per share, in the prior year quarter. Despite the revenue decrease, EyePoint highlighted progress with EYP-1901 and improvements to the balance sheet, including a $115.1 million follow-on financing completed in February 2021.
Total net revenue for Q4 2020 was $7.1 million, down from $8.6 million in Q4 2019.
Net product revenue for Q4 2020 was $6.7 million, with $4.0 million from YUTIQ and $2.7 million from DEXYCU.
Net loss for Q4 2020 was $15.5 million, or $1.07 per share, compared to a net loss of $10.4 million, or $0.98 per share, for the prior year quarter.
Operating expenses for Q4 2020 totaled $19.9 million, compared to $17.6 million in the prior year period.
Revenue by Segment
Forward Guidance
EyePoint Pharmaceuticals anticipates that its cash on hand as of December 31, 2020, along with the net proceeds from the February 2021 public stock offering and expected net cash inflows from product sales, will be sufficient to fund operations through the second quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...